$$
\sum 1 4 1 0 0 8 9
$$

510(k) SUMMARY

1. Date:

February 28, 2014

2. Submitter:

Guangzhou Wondfo Biotech Co., Ltd. South China University of Technology Guangzhou, P.R. China 510641

3. Contact person:

Joe Shia   
LSI International Inc.   
504 East Diamond Ave., Suite I Gaithersburg, MD 20877   
Telephone: 240-505-7880   
Fax: 301-916-6213.   
Email:shiajl@yahoo.com

4Device Name: Classification:

# CR3 Keyless Split Sample Cup Morphine-Oxazepam

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>CFR#</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DJG</td><td rowspan=1 colspan=1>21 CFR, 862.3650 Opiate Test System</td><td rowspan=1 colspan=1>Toxicology</td></tr><tr><td rowspan=1 colspan=1>JXM</td><td rowspan=1 colspan=1>21 CFR, 862.3170 Benzodiazepine Test System</td><td rowspan=1 colspan=1>Toxicology</td></tr></table>

Predicate Devices:

Guangzhou Wondfo Biotech Co., Ltd. Wondfo Multi-Drug Urine Test Cup (Panel) (K130665)

6Intended Use

CR3 Keyless Split Sample Cup Morphine-Oxazepam is a rapid test for the qualitative detection of Morphine (a drug in the opiate class) and Oxazepam(a drug in the benzodiazepine class) in human urine at a cutoff concentration of $2 0 0 0 \mathrm { { n g / m L } }$ and $3 0 0 \mathrm { n g / m L }$ , respectively.

The tests may yield preliminary positive results even when prescription drugs including Morphine and Oxazepam are ingested, at prescribed doses; it is not intended to distinguish between prescription use or abuse of these drugs. There are no uniformly recognized cutoff concentration levels for morphine and oxazepam in urine. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

For in vitro diagnostic use only. It is intended for over-the-counter and for prescription use.

Device Description

Immunochromatograph assays for Opiate and Benzodiazepines Urine Tests use a lateral flow, one step system for the qualitative detection of Morphine and Oxazepam in human urine. Each assay uses a monoclonal antibody-dye conjugate against drugs with gold chloride and fixed drug-protein conjugates and anti-mouse IgG polyclonal antibody in membranes.

8. Substantial Equivalence Information

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Indication(s) foruse</td><td rowspan=1 colspan=1>For the qualitative determination ofMorphine, Oxazepam individual inhuman urine.</td><td rowspan=1 colspan=1>Same (but the number ofdrugs detected different)</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive binding, lateral flowimmunochromatographic assays basedon the principle of antigen antibodyimmunochemistry.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type Of Test</td><td rowspan=1 colspan=1>Immunoassay principles that rely onantigen-antibody interactions to indicatepositive or negative result</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut Off Values</td><td rowspan=1 colspan=1>Morphine: 2000ng/mlOxazepam: 300ng/ml</td><td rowspan=1 colspan=1>Same (but the numberof drugs detecteddifferent)</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Split Keyless Cup</td><td rowspan=1 colspan=1>Cup, Dip Card</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>OTC Use &amp; Prescription Use</td><td rowspan=1 colspan=1>Same</td></tr></table>

Test Principle

It is a rapid test for the qualitative detection of Morphine and Oxazepam in urine samples. It is a lateral flow chromatographic immunoassay. When the absorbent end is immersed into a urine sample, the urine is absorbed into the device by capillary action and mixes with the antibody-dye conjugate, flowing across the pre-coated membrane. At analyte concentration below the target cut off, antibody-dye conjugates bind to the drug-protein conjugate immobilized in the Test Region (T) of the device. This produces a colored test line that indicates a negative result. When analyte concentration is above the cutoff, analyte molecules bind to the antibody-dye conjugate, preventing the antibody-dye conjugate from binding to the drug-protein conjugate immobilized in the Test Region (T) of the device. No colored band shows in the test region, indicating a preliminary positive result.

10. Performance Characteristics

1. Analytical Performance

a. Precision

Precision studies were carried out for samples with concentrations of - $100 \%$ cut off, $. 7 5 \%$ cut off, $- 5 0 \%$ cut off, $- 2 5 \% 0 0$ off, $+ 2 5 \%$ cut off, $+ 5 0 \%$ cut off , $+ 7 5 \% c \mathrm { u t }$ off and $+ 1 0 0 \%$ cut off. For each concentration, tests were performed two runs per day for 25 days with three different lots of devices. The results obtained are summarized in the following table.

A. For Morphine testing

<table><tr><td rowspan=1 colspan=1>ResultOPI</td><td rowspan=1 colspan=1>-100%cut off</td><td rowspan=1 colspan=1>-75%cut off</td><td rowspan=1 colspan=1>-50%cut off</td><td rowspan=1 colspan=1>-25%Cut off</td><td rowspan=1 colspan=1>cut off</td><td rowspan=1 colspan=1>+25%cut off</td><td rowspan=1 colspan=1>+50%cut off</td><td rowspan=1 colspan=1>+75%cut off</td><td rowspan=1 colspan=1>+100%cut off</td></tr><tr><td rowspan=1 colspan=1>W11510201CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>W11510202CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>44+/6-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50÷/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>W11510203CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

# B. For Oxazepam testing

<table><tr><td rowspan=1 colspan=1>ResultBZO</td><td rowspan=1 colspan=1>-100%cut off</td><td rowspan=1 colspan=1>-75%cut off</td><td rowspan=1 colspan=1>-50%cut off</td><td rowspan=1 colspan=1>-25%Cut off</td><td rowspan=1 colspan=1>cut off</td><td rowspan=1 colspan=1>+25%cut off</td><td rowspan=1 colspan=1>+50%cut off</td><td rowspan=1 colspan=1>+75%cut off</td><td rowspan=1 colspan=1>+100%cut off</td></tr><tr><td rowspan=1 colspan=1>W11510201CU5</td><td rowspan=1 colspan=1>50-0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>W11510202CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>43+/7.</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>W11510203CU5</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>42+/8-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

b. Linearity Not applicable

c. Stability It is stable at $4 { - } 3 0 ^ { \circ } \mathrm { C }$ for 18 months.

d.Cut-off

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Cut-off (ng/ml)</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>2000</td></tr><tr><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>300</td></tr></table>

e. Interference

Compounds that show no interference at a concentration of $1 0 0 ~ \mu \mathrm { g / m L }$ are summarized in the following tables.

# Morphine

4-Acetamidophenol Ecgonine methylester Oxolinic acid Acetophenetidin (-) -Y -Ephedrine Oxymetazoline N-Acetylprocainamide Erythromycin Papaverine Acetylsalicylic acid EPY $\beta$ -Estradiol Penicillin-G Aminopyrine Estrone-3-sulfate Pentazocine Amitryptyline Ethyl-p-aminobenzoate Pentobarbital Amobarbital Fenoprofen Perphenazine Amoxicillin Furosemide Phencyclidine

Ampicillin   
Ascorbic acid   
D,L-Amphetamine   
Apomorphine   
Aspartame   
Atropine   
Benzilic acid   
Benzoic acid   
Benzoylecgonine   
Benzphetamine   
Bilirubin $( \pm )$   
Brompheniramine   
Caffeine   
Cannabidiol   
Chloralhydrate   
Chiloramphenicol   
Chlordiazepoxide   
Chlorothiazide   
EPY $( \pm )$ Chlorpheniramine   
Chlorpromazine   
Chlorquine   
Cholesterol   
Clomipramine   
Clonidine   
Cocaine hydrochloride   
Cortisone   
(-) Cotinine   
Creatinine   
Deoxycorticosterone   
Dextromethorphan   
Diazepam   
Diclofenac   
Diflunisal   
Digoxin   
Diphenhydramine   
Doxylamine   
Ecgonine hydrochlorid   
Oxazenam   
Phenelzine   
Phenobarbital   
Phentermine   
L-Phenylephrine   
E $\beta$ Phenylethylamine   
Phenylpropanolamine   
Prednisone   
D,L-Propanolol   
D-Propoxyphene   
D-Pseudoephedrine   
Quinidine   
Quinine   
Ranitidine   
Salicylic acid   
Secobarbital   
Serotonin (5-   
Hydroxytyramine)   
Sulfamethazine   
Sulindac   
Temazepam   
Tetracycline   
Tetrahydrocortisone, 3 Acetate   
Tetrahydrocortisone3 ( B -D   
glucuronide)   
Tetrahydrozoline   
Thiamine   
Thioridazine   
D, L-Tyrosine   
Tolbutamide   
Triamterene   
Trifluoperazine   
Trimethoprim   
Trimipramine   
Tryptamine   
D, L-Tryptophan   
Tyramine   
Uric acid   
Verapamil   
Zomepirac   
Oxolinic acid   
Gentisic acid   
Hemoglobin   
Hydralazine   
Hydrochlorothiazide   
Hydrocortisone   
O-Hydroxyhippuric acid   
p-Hydroxy methamphetamine   
3-Hydroxytyramine   
Ibuprofen   
Imipramine   
Iproniazid   
Isoproterenol   
Isoxsuprine   
Ketamine   
Ketoprofen   
Labetalol   
Loperamide   
Maprotiline   
Meperidine   
Meprobamate   
Methadone   
Methoxyphenamine   
$( + )$ 3,4-Methylenedioxy  
amphetamine   
$( + ) ^ { 3 , 4 }$ -Methylenedioxy  
methamphetamine   
Nalidixic acid   
Nalorphine   
Naloxone   
Naltrexone   
Naproxen   
Niacinamide   
Nifedipine   
Norethindrone   
D-Norpropoxyphene   
Noscapine   
D,L-Octopamine   
Oxalic acid   
Oxazepam

#

4-Acetamidophenol Acetophenetidin N-Acetvprocainamide Acetvsalicvlic acid Aminopvrine

Doxylamine   
Ecaonine dydrochloride   
Ecqonine methylester   
(-)-Y-Ephedrine   
Fenoprofen

Pentobarbital Perphenazine Phencyclidine Phenelzine

Amityptvline Furosemide Phenobarbital   
Amorbarbital Gentisic acid Phentermine   
Amoxicillin Hemoglobin L-Phenylephrine   
Ampicillin Hydrocortisone $\beta$ Phenylethylamine   
l-Ascorbic Acid O-Hydroxyhippuric acid Phenylpropanotamine   
D.L-Amphetamine p-Hydroxy- methamphetamine Prednisone   
Apormorphine 3-Hydroxytyramine D.L-Propanolol   
Aspartame Ibuprofen D-Propoxyphene   
Atropine Imipramine D-Pseudoephedrine   
Benzillic acid Iproniazid Quinine   
Benzoic acid EMP $( \pm )$ Isoproterenol Ranitidine   
Benzoylecaonine Isoxsuprine Salicylic acid   
Benzphetamine Ketamine Secobarbital   
Bilirubin Ketoprofen Serotonin (5-Hydroxytyramine)   
$( \pm )$ Chlorpheniramine Labetalol Sertraline   
Caffeine Loperamide Sulfamethazine   
Cannabidiol Maprotiline Sulindac   
Chloralhvdrate Meperidine Tetrahydrocortisone,3 Acetate   
Chloramphenicol Meprobamate Tetrahydrocortisone,(β-D glucuronide)   
Chlorothiazide Methadone Tetrahydrozoline   
EPY $( \pm )$ Chlorpheniramine Methoxyphenamine Thiamine   
Chlorpromazine EPY $( + )$ 3,4-Methylenedioxy- Thioridazine amphetamine   
Chlorquine $^ { ( + ) 3 , 4 }$ Methylenedioxy- D.L-Tyrosine methamphetamine   
Cholesterol Nalidixic acid Tolbutamide   
Clomipramine Nalorphine Triamterene   
Clonidine Naloxone Trifluoperazine   
Cocaine hydrochloride Naltrexone Trimethoprim   
Cortisone Naproxen Triyptamine   
(-)cotinine Niacinamide D.L-Tryptophan   
Creatinine Nifedipine Tyramine   
Dextromethlorphan Norethindrone Uric acid   
Diclolrfenac D-Norpropoxyphene Verapamil   
Diflunisal Noscapine Zomepirac   
Diaoxin D.L-Octopamine   
Diphenhydramine Oxalic acid

# f. Specificity/Cross-Reactivity

To test the specificity/cross-reactivity, drug metabolites and other components that are likely to be present in urine samples were tested. Compounds that produced positive results are listed below.

<table><tr><td rowspan=1 colspan=1>Morphine, Cutoff=2000 ng/mL</td><td rowspan=1 colspan=1>ResultPositive at 2,000 ng/mL</td><td rowspan=1 colspan=1>%Cross-Reactivity100%</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>Positive at 2,000 ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Ethylmorphine</td><td rowspan=1 colspan=1>Positive at 5,000 ng/mL</td><td rowspan=1 colspan=1>40%</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>Positive at 12,500 ng/mL</td><td rowspan=1 colspan=1>16%</td></tr><tr><td rowspan=1 colspan=1>Hydromorphine</td><td rowspan=1 colspan=1>Positive at 5,000 ng/mL</td><td rowspan=1 colspan=1>40%</td></tr><tr><td rowspan=1 colspan=1>Levorphanol</td><td rowspan=1 colspan=1>Positive at 75,000 ng/mL</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=1 colspan=1>σ-Monoacetylmorphine</td><td rowspan=1 colspan=1>Positive at 5,000 ng/mL</td><td rowspan=1 colspan=1>40%</td></tr><tr><td rowspan=1 colspan=1>Morphine 3-b-D-glucuronide</td><td rowspan=1 colspan=1>Positive at 2,000 ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Norcodeine</td><td rowspan=1 colspan=1>Positive at 12,500 ng/mL</td><td rowspan=1 colspan=1>16%</td></tr><tr><td rowspan=1 colspan=1>Normorphone</td><td rowspan=1 colspan=1>Positive at 50,000 ng/mL</td><td rowspan=1 colspan=1>4%</td></tr><tr><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>Positive at 25,000 ng/mL</td><td rowspan=1 colspan=1>8%</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone</td><td rowspan=1 colspan=1>Positive at 25,000 ng/mL</td><td rowspan=1 colspan=1>8%</td></tr><tr><td rowspan=1 colspan=1>Procaine</td><td rowspan=1 colspan=1>Positive&#x27;at 150,000ng/mL</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Thebaine</td><td rowspan=1 colspan=1>Positive at 100,000ng/mL</td><td rowspan=1 colspan=1>2%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Oxazepam, Cutoff=300 ng/mL</td><td rowspan=1 colspan=1>ResultPositive at 300 ng/mL</td><td rowspan=1 colspan=1>%Cross-Reactivity100%</td></tr><tr><td rowspan=1 colspan=1>Alprazolam</td><td rowspan=1 colspan=1>Positive at 200 ng/mL</td><td rowspan=1 colspan=1>150%</td></tr><tr><td rowspan=1 colspan=1>a-Hydroxyalprazolam</td><td rowspan=1 colspan=1>Positive at 1,500 ng/mL</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>Bromazepam</td><td rowspan=1 colspan=1>Positive at 1,500 ng/mL</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>Chlordiazepoxide</td><td rowspan=1 colspan=1>Positive at 1,500 ng/mL</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>Clonazepam HCI</td><td rowspan=1 colspan=1>Positive at 800 ng/mL</td><td rowspan=1 colspan=1>37.5%</td></tr><tr><td rowspan=1 colspan=1>Clobazam</td><td rowspan=1 colspan=1>Positive at 100 ng/mL</td><td rowspan=1 colspan=1>300%</td></tr><tr><td rowspan=1 colspan=1>Clonazepam</td><td rowspan=1 colspan=1>Positive at 800 ng/mL</td><td rowspan=1 colspan=1>37.5%</td></tr><tr><td rowspan=1 colspan=1>Clorazepate dipotassium</td><td rowspan=1 colspan=1>Positive at 200 ng/mL</td><td rowspan=1 colspan=1>150%</td></tr><tr><td rowspan=1 colspan=1>Delorazepam</td><td rowspan=1 colspan=1>Positive at 1,500 ng/mL</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>Desalkylflurazepam</td><td rowspan=1 colspan=1>Positive at 400 ng/mL</td><td rowspan=1 colspan=1>75%</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>Positive at 200 ng/mL</td><td rowspan=1 colspan=1>150%</td></tr><tr><td rowspan=1 colspan=1>Estazolam</td><td rowspan=1 colspan=1>Positive at 2,500 ng/mL</td><td rowspan=1 colspan=1>12%</td></tr><tr><td rowspan=1 colspan=1>Flunitrazepam</td><td rowspan=1 colspan=1>Positive at 400 ng/mL</td><td rowspan=1 colspan=1>75%</td></tr><tr><td rowspan=1 colspan=1>D,L-Lorazepam</td><td rowspan=1 colspan=1>Positive at 1,500 ng/mL</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>Midazolam</td><td rowspan=1 colspan=1>Positive at 12,500 ng/mL</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1>Nitrazepam</td><td rowspan=1 colspan=1>Positive at 100 ng/mL</td><td rowspan=1 colspan=1>300%</td></tr><tr><td rowspan=1 colspan=1>Norchlordiazepoxide</td><td rowspan=1 colspan=1>Positive at 200 ng/mL</td><td rowspan=1 colspan=1>150%</td></tr><tr><td rowspan=1 colspan=1>Nordiazepam</td><td rowspan=1 colspan=1>Positive at 400 ng/mL</td><td rowspan=1 colspan=1>75%</td></tr><tr><td rowspan=1 colspan=1>Temazepam</td><td rowspan=1 colspan=1>Positive at 100 ng/mL</td><td rowspan=1 colspan=1>300%</td></tr><tr><td rowspan=1 colspan=1>Trazolam</td><td rowspan=1 colspan=1>Positive at 2,500 ng/mL</td><td rowspan=1 colspan=1>12%</td></tr></table>

g. Effects of Urine Density and pH Density (Specific Gravity)

12 urine samples with density ranges (1.000-1.035) are collected and spiked with each drug at $2 5 \%$ below and $2 5 \%$ above cutoff levels. Each sample was tested by three batches of CR3 Keyless Split Sample Cup Morphine-Oxazepam. It shows that urine density does not affect test results.

# Effect of Urine pH

The pH of an aliquot negative urine pool is adjusted to a $\mathsf { p H }$ range of 4 to 9 in $1 \mu \mathrm { H }$ unit increments and spiked with each drug at $25 \%$ below and $2 5 \%$ above cutoff levels. Each sample was tested by three batches of CR3 Keyless Split Sample Cup Morphine-Oxazepam. It shows that urine pH does not interfere with the performance of the test.

# 2. Comparison Studies

The method comparison for the CR3 Keyless Split Sample Cup Morphine-Oxazepam was performed in-house with three laboratory assistants with relevant experience and a lay person with no experience other than reading the instructions for use. Operators ran 80 (40 negative and 40 positive) unaltered clinical samples. The samples were blind labeled and compared to GC/MS results. The results are presented in the table below:

# Morphine

<table><tr><td rowspan=1 colspan=1>GroupOperator</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Low Negativeby GC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>LayPerson</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant table:   

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample number</td><td colspan="1" rowspan="1">GC/MS result</td><td colspan="1" rowspan="1">Viewer result</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">OPIC1061</td><td colspan="1" rowspan="1">1997</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">OPIC1064</td><td colspan="1" rowspan="1">1994</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">OPIC1065</td><td colspan="1" rowspan="1">2025</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">OPIC1061</td><td colspan="1" rowspan="1">1997</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">OPIC1062</td><td colspan="1" rowspan="1">. 1943</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">OPIC1063</td><td colspan="1" rowspan="1">2043</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">OPIC1064</td><td colspan="1" rowspan="1">1994</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">OPIC1065</td><td colspan="1" rowspan="1">2025</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">OPIC1061</td><td colspan="1" rowspan="1">1997</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">OPIC1063</td><td colspan="1" rowspan="1">2043</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">OPIC1064</td><td colspan="1" rowspan="1">1994</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">OPIC1065</td><td colspan="1" rowspan="1">2025</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Lay person</td><td colspan="1" rowspan="1">OPIC1061</td><td colspan="1" rowspan="1">1997</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay person</td><td colspan="1" rowspan="1">OPIC1062</td><td colspan="1" rowspan="1">1943</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay person</td><td colspan="1" rowspan="1">OPIC1063</td><td colspan="1" rowspan="1">2043</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Lay person</td><td colspan="1" rowspan="1">OPIC 1064</td><td colspan="1" rowspan="1">1994</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay person</td><td colspan="1" rowspan="1">OPIC1065</td><td colspan="1" rowspan="1">2025</td><td colspan="1" rowspan="1">negative</td></tr></table>

Oxazepam   

<table><tr><td rowspan=1 colspan=1>GroupOperatoks</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Low Negativeby GC/MS(less than-50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between thecutoff and+50%)</td><td rowspan=1 colspan=1>High Positiveby GC/MS(greater than+50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>LayPerson</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant table:   

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample number</td><td colspan="1" rowspan="1">GC/MS result</td><td colspan="1" rowspan="1">viewer results</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BZOC1062</td><td colspan="1" rowspan="1">291</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BZOC1064</td><td colspan="1" rowspan="1">296</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BZOC1093</td><td colspan="1" rowspan="1">358</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">BZOC1095</td><td colspan="1" rowspan="1">344</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BZOC1062</td><td colspan="1" rowspan="1">291</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BZOC1063</td><td colspan="1" rowspan="1">312</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BZOC1064</td><td colspan="1" rowspan="1">296</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">BZOC1065</td><td colspan="1" rowspan="1">288</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BZOC1063</td><td colspan="1" rowspan="1">312</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BZOC1064</td><td colspan="1" rowspan="1">296</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BZOC1065</td><td colspan="1" rowspan="1">288</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BZOC1092</td><td colspan="1" rowspan="1">357</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BZOC1093</td><td colspan="1" rowspan="1">358</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">BZOC1095</td><td colspan="1" rowspan="1">344</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BZOC1062</td><td colspan="1" rowspan="1">291</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay person</td><td colspan="1" rowspan="1">BZOC1064</td><td colspan="1" rowspan="1">296</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay person</td><td colspan="1" rowspan="1">BZOC1065</td><td colspan="1" rowspan="1">288</td><td colspan="1" rowspan="1">positive</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BZOC1063</td><td colspan="1" rowspan="1">312</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BZOC1092</td><td colspan="1" rowspan="1">357</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BZOC1093</td><td colspan="1" rowspan="1">358</td><td colspan="1" rowspan="1">negative</td></tr><tr><td colspan="1" rowspan="1">Lay Person</td><td colspan="1" rowspan="1">BZOC1095</td><td colspan="1" rowspan="1">344</td><td colspan="1" rowspan="1">negative</td></tr></table>

# Lay-user study

A lay user study was performed at three intended user sites with 260 lay persons. Participants in the study were 79 males and 47 females tested the Morphine samples, 74 males and 60 females tested the Oxazepam samples. They had diverse educational and professional backgrounds and ranged in age from 21 to $> 5 0$ . Urine samples were prepared at the following concentrations; $- 1 0 0 \% _ { 0 } + 1 - 7 5 \% _ { 0 } + 1 - 5 0 \% _ { 0 } + 1 - 2 5 \%$ of the cutoff by spiking drug(s) into drug free-pooled urine specimens. The concentrations of the samples were confirmed by GC/MS. Each sample was aliquoted into individual containers and blind-labeled. Each participant was provided with the package insert, I blind labeled samples and a device.The results are summarized below.

<table><tr><td rowspan=1 colspan=2>Cup format</td><td rowspan=1 colspan=1>Number of</td><td rowspan=1 colspan=2>OTC user</td><td rowspan=2 colspan=1>%AgreementWith GC/MS</td></tr><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>samples</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Drug -free</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=6 colspan=1>Morphine</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=6 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr></table>

3. Clinical Studies Not applicable

# 11. Conclusion

Based on the test principle and performance characteristics of the device, it's concluded that CR3 Keyless Split Sample Cup Morphine-Oxazepam is substantially equivalent to the predicate.

April 8, 2014

GUANGZHOU WONDFO BIOTECH CO., LTD. C/O JOE SHIA   
504 EAST DIAMOND AVE.   
SUITE F   
GAITHERSBURG MD 20878

Re: K140089 Trade/Device Name: CR3 Keyless Split Sample Cup Morphine-Oxazepam Regulation Number: 21 CFR 862.3650 Regulation Name: Opiate test system Regulatory Class: II Product Code: DJG, JXM Dated: January 06, 2014 Received: January 14, 2014

Dear Mr. Shia:

We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2—Mr. Shia

1f you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 89 please contact the Division of Small Manufacturers. International and Consumer   
Assistance at its toll-frce number (800) 638 2041 or (301) 796-7100 or al its Internet address htp://www.fda.gov/MedicalDeviccs/ResourcesforYou/lndustry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse cvents under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilitics under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-frec number (800) 638-2041 or (301) 796-7100 or at its Internct address http://wwv.fda.gov/McdicalDevices/ResourcesforYou/lndustry/default.htm.

Sincerely yours,

# Courtney H. Lias -S

Courtney H. Lias. Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

510(k) Number (if known) K140089

Device Name CR3 Keyless Split Sample Cup Morphine-Oxazepan

indications for Use (Describe)   
CR   S Ox  e  e hi and 30ong/mL, respectively.

The t my elia osiveul eve whe petin dr ncdigMorhian Oxaze ouniormly recogniz cutoconcntration evelormorphine and oxazepam in rine. The et provie py  esusmoseciv hlmemus eusr tain c h yCnat  osau be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

For in vitro diagnostic usc only. It is intended for over-the-counter and for prescription use.

Avis T. Danishefsky -S

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden tme orhis coleclionnformation is stmated o averagehours per esponsencudi time to review instruclions, search existing data sources, gather and maintain the data needed and complele and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@Ida.hhs.gov

"An agency may not conducl or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OM8 number."